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EugenolThis publication introduces a series of six other publications describing the toxicological assessment of
kretek cigarettes, i.e., cigarettes characterized primarily by the use of a signiﬁcant amount of cloves as
an ingredient added to the tobacco. This paper presents background information on kretek cigarettes,
describes the general approach of the in vitro and in vivo toxicological assessment of mainstream smoke
from kretek cigarettes, presents the methodology used, and summarizes the results of the assessment
program. In summary, the smoke from kretek cigarettes gives rise to the typical cigarette smoke-related
effects known from American-blended cigarettes, does not reveal any novel toxicity, and exhibits an
unexpected distinct attenuation of pulmonary inﬂammation. Based on equal amounts of smoke total par-
ticulate matter (TPM), kretek cigarettes deliver less toxicants when compared to American-blended cig-
arettes; when assessed in vitro, the smoke from kretek cigarettes is less cytotoxic (gas/vapor phase) and
less mutagenic (TPM). When assessed in vivo, kretek cigarette smoke shows lower toxicity in the respi-
ratory tract. When based on an equal nicotine basis, several of the toxicity endpoints in kretek cigarettes
become equivalent to American-blended cigarettes. The data do not indicate an increased hazard poten-
tial of kreteks compared to American-blended cigarettes.
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Background signiﬁcant amount of cut cloves, the sun-dried ﬂower buds of the1.1. General
This publication introduces a series of six other publications
describing the in vitro and in vivo toxicological assessment of kre-
tek cigarettes. The assessment is intended to ﬁll a gap in hazard
characterization using data obtained in a rigorous Good Laboratory
Practice (GLP) environment using International Conference on Har-
monization (ICH) and Organisation for Economic Co-operation and
Development (OECD) guideline-based toxicity assays. This paper
gives background information, describes the general approach,
then presents the methods and summarizes the results of the
assessment that are outlined in detail in the other publications of
the series.
1.2. History of kretek cigarettes
Kretek cigarettes are a type of cigarettes originating from Indo-
nesia. These cigarettes are primarily characterized by the use of aclove tree (Syzygium aromaticum, syn. Eugenia aromaticum), added
to the tobacco since the early 1880s. The addition of cloves was
thought to help cure sore throat and relieve asthma by transfer
of eugenol to mainstream smoke (MS). Eugenol is known for its
antiseptic (Hemaiswarya and Doble, 2009), anti-inﬂammatory
(Rodrigues et al., 2009; Yogalakshmi et al., 2010), and anesthetic
(Sell and Carlini, 1976; Guenette et al., 2006) properties. Accord-
ingly, kretek cigarettes could be purchased in local pharmacies.
Originally, kretek cigarettes were hand-rolled products, either
paper-wrapped or wrapped in ironed corn husks, and became the
preferred cigarette type for smokers with a lower income. The
uneven hand-rolled, essential oil-spotted appearance might have
added to the disfavor of the richer population to smoke these prod-
ucts. This disfavor remained until the late 1960s. In the mid-1970s
the production partly changed to machine-made products, but it
was only in the mid-1980s that machine production exceeded
the hand-rolling process. Today kretek cigarettes are the preferred
cigarette type in Indonesia with a market share of some 92% (WHO,
2009). Other countries with some market share are Malaysia
(2.9%), Singapore (4.4%), Brunei (9.9%), India (0.3%), and Brazil
(0.5%).
In the early 1980s, kretek cigarettes became rather popular in
the USA among young people, particularly in California high
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into the USA totaled 150 million kretek cigarettes/year (CDC,
1985). However, the imports declined sharply in 1985 to 50 mil-
lion, reportedly because of publicity regarding suspected adverse
events (Guidotti et al., 1987, 1989). In addition, public health orga-
nizations in the USA and elsewhere were concerned with both
higher yields of tar and nicotine per cigarette when compared to
non-kretek marketed cigarettes and earlier smoking initiation
although data on kretek use trajectories were virtually absent. In
2009, the USA prohibited cigarettes with a characterizing ﬂavor
other than tobacco or menthol, which explicitly includes a ban
on cigarettes with a ﬂavor of clove (FDA, 2009). This ban has been
challenged by Indonesia at the World Trade Organization. Brazil,
with a small market share of kretek cigarettes, has enacted a broad
ingredients ban in 2012, which includes a ban on menthol and
clove cigarettes. However, the ingredients ban is not currently in
effect due to a court order in the pending litigation.
1.3. Product characteristics
The name kretek is an onomatopoeia, i.e., a word for an object
that imitates the sound the object is producing; here the crackling
noise that cloves make when burned: ‘kretek kretek’. The inclusion
of cloves gives these cigarettes their distinctive taste and smell and
may result in a perceived smoothness of the smoke (Guidotti et al.,
1989). The clove content of the kretek cigarettes varies typically
between 20% and 40% (w/w). Dried cloves contain up to 20% vola-
tile ﬂavoring compounds, the volatile fraction is predominantly
(85%) composed of eugenol (2-methoxy-4-(2-propenyl)phenol).
Thus, the ﬁller (tobacco and additives) of kretek cigarettes may
contain up to 7% (w/w) eugenol. Other main volatiles in cloves
are eugenol acetate, caryophyllene, a-humulene, and methyl euge-
nol (Stanﬁll et al., 2003; Jirovetz et al., 2006; Musenga et al., 2006;
Chaieb et al., 2007). Furthermore, unlike to American-blended cig-
arettes, kretek cigarettes in Indonesia are made predominantly
from domestic tobaccos. Most of them are from Java, Sumatra, Bali,
and Lombok, supplying the industry with virtually some hundreds
types of tobacco, different in variety and grades. In addition to this
diversity, the green tobacco leaves might have been cut in stripes
before drying (Rajangan) or left intact as whole leaf (Krosok).
Nearly all of these tobaccos are sun dried. There are typically more
than 20 tobacco varieties in a blend of a kretek. Beside tobacco and
ground cloves, there is a third component of the kretek cigarettes:
the sauce (Polzin et al., 2007). The sauce is a mixture of substances
that keeps the tobacco moist, helps facilitating the manufacturing
process, and provides distinctive tobacco tastes and aromas in a lit
kretek cigarette upon smoking. Historically, many tobacco farmers
applied a sauce of undisclosed composition to the tobacco before
delivery to the cigarette manufacturers. Today, most of the larger
manufacturers add the ingredients themselves to the tobacco in
the factory, which allows companies to evaluate the ingredients
used in order to ensure that they do not increase the inherent tox-
icity of the smoke at the use level. Kretek cigarettes are sold with
and without ﬁlters. Due to their construction and cut ﬁller weight,
tar, nicotine and carbon monoxide (CO) yields are often higher in
kretek cigarettes compared to other marketed cigarettes. TPM
yields of 60 mg/cigarette when smoked according to the standard
International Organization for Standardization machine-smoking
regimen (IARC, 1985) are at the high end.
1.4. Socioeconomic aspects
Most kretek cigarettes are manufactured and consumed domes-
tically in Indonesia. Interestingly, due to a taxation system that
taxes machine-made kretek cigarettes at a much higher rate than
hand-rolled kretek cigarettes, approximately one third of thekretek cigarettes are still today hand-rolled in factories, providing
employment for around 200,000 Indonesians, most of them
women. An additional 4–17 million people are estimated to be in
occupations in Indonesia that are indirectly linked to the manufac-
ture of kretek cigarettes. As such the kretek industry constitutes
the second largest employer after the Indonesian Government
(Arnez, 2009).
The three largest kretek cigarette manufacturers are Gudang
Garam, Djarum, and H.M. Sampoerna. Together, these companies
have a share in the Indonesian market of 65%. Other manufacturers
are Bentoel International and Saritoga and a large number of local
providers with a marginal market share. A signiﬁcant volume of
kretek cigarettes is now exported to many countries around the
world. The export of kretek cigarettes from Indonesia amounts to
500 million USD/year (Yulisman, 2012).2. Existing studies on health risks
Although the health effects of kretek cigarette smoking in Indo-
nesia has not been systematically studied, it is likely that adverse
effects additional to those associated with conventional cigarettes
would have been identiﬁed in the traditional Indonesian market,
that represents a population of more than 85 million adult kretek
cigarette smokers (WHO, 2013). For example, in a review entitled
‘Report on Tobacco in Indonesia’ no adverse effects other than
those that are typically grouped as ‘smoking-related diseases’ have
been reported (Djutaharta and Surya, 2003). Other reviews of ‘non-
cigarette tobacco products’ which included kretek cigarettes
reported no novel ﬁndings in addition to those reported previously
(Prignot et al., 2008; O’Connor, 2012). In a study on Indonesian
woodworkers, no relationship between an increase in respiratory
symptoms and kretek cigarette smoking could be found, but there
was an inverse relationship between airway obstruction and smok-
ing, although the difference was not statistically signiﬁcant. The
authors suggested that a special smoking behavior of kretek ciga-
rette smokers might be the cause for the lack of adverse outcomes,
i.e., ‘‘which is probably explained by the type of cigarette (kretek),
in which smoke is usually not inhaled’’ (Borm et al., 2002).
In the USA (75,000 smokers in 1984 (Guidotti, 1985)), particu-
larly in California, a few case reports linked kretek cigarette smoke
inhalation with an increased risk of pulmonary adverse events,
including hemoptysis, aspiration pneumonitis, and respiratory
infection (Anderson, 1985; CDC, 1985; Guidotti et al., 1987,
1989; AMA, 1988). There have also been a small number of idio-
syncratic reports, in which hypotheses have been generated to link
kretek cigarette smoking together with some other factors to the
causation of an illness, such as high-altitude pulmonary edema
(Hackett et al., 1985).
The Centers for Disease Control and Prevention (CDC) in the
USA have reported 12 cases of non-speciﬁc respiratory illness in
individuals with an alleged close temporal relationship to smoking
kretek cigarettes. However, they also state that a cause-and-effect
relationship between smoking kretek cigarettes and illness in these
patients has not been proven (CDC, 1985). It should be noted that
amongst the case reports of people who experienced severe symp-
toms, were those who had smoked in the presence of, or immedi-
ately following, acute respiratory infections. In response to this
potential association, the CDC maintains a Fact Sheet stating that
‘Kretek cigarette smoking is associated with an increased risk for
acute lung injury (i.e., lung damage that can include a range of
characteristics such as decreased oxygen, ﬂuid in the lungs, leakage
from capillaries, and inﬂammation), especially among susceptible
individuals with asthma or respiratory infections’ (CDC, 2014).
Similar statements have been repeated by both the American
Lung Association and the American Academy of Pediatrics
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cigarettes may induce bronchospasm in those with a history of
asthma, and that aspiration pneumonia may result from a dimin-
ished gag reﬂex induced by the anesthetic action of eugenol. The
limited reports that have been noted occurred during the 1980s,
with no subsequent adverse reports being published thereafter.
A small open-label, within-subjects design, clinical study
examined the smoking behavior between kretek cigarettes vs.
American-blended cigarettes smokers by sampling plasma nicotine
levels (Malson et al., 2003). The subjects had some experience with
kretek cigarettes and smoked either one kretek cigarette or one
cigarette of their own brand. Recording of the pharmacokinetic
proﬁle of nicotine revealed no difference in nicotine uptake,
suggesting that smokers inhaled kretek cigarette smoke, and that
machine-smoked deliveries are a misleading surrogate of actual
exposure to the smoke.3. Results from previously conducted animal inhalation studies
A limited number of animal studies have been published on the
inhalation toxicology of kretek cigarette MS more than two dec-
ades ago. LaVoie et al. reported on 2 studies they had performed
(LaVoie et al., 1986). One study concerned the intratracheal instil-
lation of eugenol and the other the sub-acute inhalation of kretek
cigarette smoke. Intratracheal administration of a single bolus of
eugenol diluted in an emulsiﬁer in rats (up to 24 mg/kg body
weight) and hamsters (up to 96 mg/kg bw) produced overt toxicity
in the lung in this model with an LD50 of 11 mg/kg bw and 17 mg/
kg bw for rats and hamsters, respectively. Regarding inhalation
toxicity, the authors employed an unusual protocol of ﬁrst expos-
ing hamsters for 14 days to an increasing concentration of MS from
the Kentucky Reference Cigarette 2R1 followed by smoke exposure
from ‘Kretek Brand I’ for 5 days and ‘Kretek Brand II’ for a further
5 days. This study had no basic control or measurement of expo-
sure to smoke constituents. Under the conditions employed, the
24-day smoke inhalation study did not reveal any signiﬁcant
lesions.
In response to the above publication, a critique raised a number
of issues regarding the intratracheal instillation of eugenol (Clark,
1986). Clark subsequently also published 3 studies: an acute
(4 h) eugenol inhalation study (Clark, 1988), an acute 1-day
(Clark, 1989) and a 14-day inhalation study (Clark, 1990) using
kretek cigarette smoke and smoke of an American-blended ciga-
rette. The Clark et al. inhalation studies demonstrated lower
biological effects of kretek cigarette smoke compared to American-
blended cigarettes at all dose levels. Especially, hyperplastic and
metaplastic changes in the lung in the 14-day inhalation study
were only observed for the high concentration of the smoke of
the American-blended cigarettes. Lack of local toxic effects in the
lung as a result of eugenol exposure was further demonstrated
by the 4-h acute inhalation of pure eugenol in rats. Although this
was an acute study and therefore not indicative of effects from
long-term exposure, the dose levels were high enough to produce
clinical signs of nervous system depression in the animals (such as
abnormal breathing). Histological examination of the lungs after a
14-day observation period revealed no abnormalities. In 1989, Gui-
dotti critiqued the work of both LaVoie et al. and Clark and
included some anecdotal clinical ﬁndings (Guidotti, 1989). The
general theme of this publication was that both investigators’ work
provided insufﬁcient evidence of the hazard potential of clove cig-
arettes and indicated that further research should be carried out.
Two decades later kretek cigarette toxicity has been character-
ized in a comprehensive assessment program as described in this
series of articles. In vivo assessments were performed in basicconformity with OECD guideline 413 ‘‘subchronic 90-day inhala-
tion study in rats’’ (OECD, 1981) with special emphasis on the
histopathology of the respiratory tract, including the assessment
of pulmonary inﬂammation as measured by differentiation and
enumeration of free lung cells in broncho-alveolar lavage ﬂuid
(BALF). Smoke chemistry and OECD/ICH-based in vitro assays
complemented the assessment program. The whole program was
performed in established GLP-certiﬁed facilities.4. General approach
In addition to this overview publication, the toxicological
assessment of kretek cigarette smoke as presented in this series
of publications is covering 3 main topics:
(1) Characterization (Part 2 (Piadé et al., 2014a) and Part 3
(Piadé et al., 2014b)): the objective was a comparative
assessment to benchmark kretek cigarette smoke toxicity
in comparison to an American-blended cigarette: Two high
selling kretek cigarettes from the Indonesian market were
included that were situated near each end of TPM deliveries
of this type of product category, i.e., one at 16 and the other
at 46 mg/cigarette, when machine-smoked according to the
ISO smoking regimen. In addition, a kretek ‘reference’ ciga-
rette with 34 mg TPM delivery was constructed and
included that constitutes a typical kretek cigarette with con-
struction characteristics that, for the typical parameters
(e.g., ﬁller weight, ﬁller composition, ﬁlter efﬁciency, paper
porosity) were close to the middle of the parameter range
found for kretek cigarettes in the Indonesian market. As
such, this kretek reference cigarette (Kretek-R) can be con-
sidered as a representative cigarette for comparisons of kre-
tek cigarettes with other tobacco product categories. The
reference cigarette 2R4F from the University of Kentucky
was included as an American-blended cigarette. This ciga-
rette is generally considered to be representative of the
12 mg ISO TPM segment of American-blended cigarettes
(Counts et al., 2006).
(2) Mechanisms (Part 4 (Roemer et al., 2014b) and Part 5
(Roemer et al., 2014c)): mechanistic studies attempting to
reveal reasons for differences between kretek cigarettes
and American-blended cigarettes: experimental cigarettes
were constructed that allow evaluating the impact of certain
product design features speciﬁc to kretek cigarettes, i.e.,
Indonesian-blended cigarette without cloves (IND), Indone-
sian or American tobacco-blended with added cloves (IND-
C, US-C), Indonesian-blended tobacco and cloves after
extraction of the oleoresins – ‘spent’ cloves (IND-SC), and
add-back to IND-SC of eugenol (IND-SC-E) and oleoresin
(IND-SC-O), and ﬁnally American-blended cigarettes with
increasing levels of eugenol (0%, 2.5%, 5%, 10%).
(3) Ingredients (Part 6 (Roemer et al., 2014a) and Part 7
(Schramke et al., 2014)): assessing the possible inﬂuence of
tobacco ingredients used in the manufacture of kretek ciga-
rettes on the biological activity of MS: In total, 350 ingredi-
ents were assigned to three ingredient mixes (A, B, and C).
Each mix was applied at a low and a high target level to test
cigarettes manufactured with a typical Indonesian blend of
tobacco and cloves representative of marketed kretek ciga-
rettes to equal weight of the control cigarette of identical
construction (cloves and humectants) but without the addi-
tion of ingredients.
This series of seven publications has been organized as out-
lined in Table 1.
Table 1
Short titles of this series of publications on the toxicity of kretek cigarettes and investigational products.
Publication
part
Short title and reference Test items
1 Background, assessment approach, and summary of ﬁndings (this
publication)
–
2 Kretek and American-blended cigarettes, smoke chemistry and in vitro
toxicity (Piadé et al., 2014a)
Marketed kretek cigarettes (Gudang Garam International Filter; A Mild 16);
kretek reference cigarette (‘Kretek-R’); vs. 2R4F
3 Kretek and American-blended cigarettes, inhalation toxicity (Piadé et al.,
2014b)
Marketed kretek cigarettes (Gudang Garam International Filter; A Mild 16);
kretek reference cigarette (‘Kretek-R’); vs. 2R4F
4 Mechanistic investigations, smoke chemistry and in vitro toxicity
(Roemer et al., 2014b)
Eugenol on American blend (2.5%, 5%, 10%) vs. control (0%); IND, IND-SC, IND-
SC-E, IND-SC-O, IND-C, and US-C*
5 Mechanistic investigations, inhalation toxicity (Roemer et al., 2014c) Eugenol on American blend (2.5%, 5%, 10%) vs. control (0%); IND, IND-SC, IND-
SC-E, IND-SC-O, IND-C, and US-C
6 The impact of ingredients added to kretek cigarettes on smoke chemistry
and in vitro toxicity (Roemer et al., 2014a)
Mix A low, Mix A high, Mix B low, Mix B high, Mix C low, Mix C high on kretek
blend vs. kretek control (0%)
7 The impact of ingredients added to kretek cigarettes on inhalation
toxicity (Schramke et al., 2014)
Mix A low, Mix A high, Mix B low, Mix B high, Mix C low, Mix C high on kretek
blend vs. kretek control (0%)
* Experimental ‘kretek cigarettes’: IND, IND-SC, IND-SC-E, IND-SC-O, IND-C, and US-C, further information see text.
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5.1. General
This section provides technical details on the methods used. The
basic set of chemical determinations and biological assays was the
same for all three topics covered in this series of publications (see
Section 4). Although it took some 5 years to complete the whole
program, the technical details of the methods remained virtually
the same over this period. The methodology as described below
has been basically the same as those used in other product assess-
ment work and has been extensively published (Carmines, 2002;
Carmines et al., 2005; Lemus et al., 2007; Gaworski et al., 2008,
2011; Moennikes et al., 2008; Patskan et al., 2008; Roemer et al.,
2008, 2009; Zenzen et al., 2012). The methods used are based on
widely accepted international testing guidelines for food and
chemicals. Some minor method variations in the course of the
studies are considered not relevant, without an impact on the out-
come of the studies. They will not be reported in detail. The major-
ity of work was carried out at Philip Morris Research Laboratories
in Cologne, Germany, (smoke chemistry and in vitro toxicity) and,
before the ban on cigarette related animal experimentation, at Phi-
lip Morris Research Laboratories in Leuven, Belgium (inhalation
toxicity). Only in one instance (assessment of pure eugenol in
American-blended cigarettes), was the work performed at the IIT
Research Institute (IITRI, Chicago, USA). For reasons of compari-
sons, differences in the response strength of the different assay
systems in the different laboratories can be eliminated, if the
reader feels this is necessary, by normalizing the data to the
response in the reference cigarette 2R4F. The single publications
in the series will not repeat the method descriptions detailed in
the present paper, but will generally refer to this publication.
5.2. Cigarettes and MS generation
The reference cigarettes 2R4F were obtained from the Univer-
sity of Kentucky, Kentucky Tobacco Research and Development
Center. American-blended cigarettes used to investigate the inﬂu-
ence of eugenol were manufactured at Philip Morris USA, Rich-
mond, USA, and those used to assess the inﬂuence of ingredients
at PT HM Sampoerna Tbk, Pandaan, Indonesia. Marketed kretek
cigarettes were obtained from the Indonesian market (Gudang
Garam International Filter and Sampoerna A Mild) or manufac-
tured for the speciﬁc study objective by PT HM Sampoerna Tbk,
Pandaan, Indonesia (Kretek-R, IND, IND-SC, IND-SC-E, IND-SC-O,
IND-C, and US-C). Further speciﬁcations are given in the individual
publications.Cigarettes were conditioned according to ISO standard 3402
(ISO, 1999), i.e., at least 48 h at target conditions of 22 ± 1 C and
a relative humidity of 60 ± 1%. Cigarettes were unpacked and
placed into open containers in the conditioning room (approxi-
mately 200 cigarettes per container). In the studies to assess the
inﬂuence of added ingredients, cigarettes were unpacked and
stored in sealed containers for a minimum of 14 h at a temperature
of 22 ± 1 C. MS was generated under ISO 3308 machine-smoking
conditions (ISO, 1991a). Minor deviations were necessary for tech-
nical reasons. The cigarettes were smoked on a 20-port Borgwaldt
rotary smoking machine (RM20H, Hamburg, Germany) for smoke
chemistry determinations and in vitro assays and on 30-port rotary
smoking machines with active side-stream exhaust (Philip Morris
Research Laboratories (PMRL), SM2000), equipped with a program-
mable dual-syringe pump (Radtke et al., 2007) for the in vivo stud-
ies. In short, puff volume, puff duration, and puff frequency for the
ISO smoking conditions were 35 ml, 2 s, and 1/min. Cigarettes were
smoked to a ﬁnal butt length of 35 mm.
The authors have chosen the ISO smoking regimen intention-
ally. They followed the conclusions of Roemer and Carchman
(2011), that more intense smoking regimens, e.g., required by
Health Canada (1999), are less efﬁcient in detecting possible differ-
ences in the yield of toxicants when comparing different cigarette
types. Furthermore, as more intense smoking regimens obviously
overestimate the smoke uptake by human smokers of cigarettes
with higher tar yields, e.g., around 10 mg ISO tar, it seems clear
that for kretek cigarettes with a yield of up to 50 mg ISO tar the
application of intense smoking regimens, leading to estimated tar
yields of far more than 100 mg, would lead to data that are not rel-
evant to the human smoker.5.3. MS chemistry
In addition to the ISO analytes (TPM, nicotine, CO, and water),
further analytes were selected based on two source documents: a
proposal that speciﬁcally focused on smoke chemistry testing from
the US Consumer Product Safety Commission (US-CPSC, 1993) and
a monograph from the International Agency for Research on Cancer
(IARC, 1985). This list has been used in a number of studies assess-
ing different cigarette designs and additives (Roemer et al., 2004;
Carmines et al., 2005; Gaworski et al., 2008; Werley et al., 2008;
Zenzen et al., 2012).
Analytes in smoke (about 50 in the individual studies) were
quantiﬁed according to established methodology as previously
described (Roemer et al., 2004):
TPM was determined gravimetrically from the smoke trapped
on glass ﬁber ﬁlters, in the following designated as Cambridge ﬁl-
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also used for the analysis of individual particle phase analytes
(see below). Nicotine was determined by gas chromatography
(GC) with either ﬂame ionization detection or nitrogen phosphorus
detector (NPD) from a 2-propanol extract of the TPM ﬁlter with
isoquinoline as internal standard. Water was determined from
the same 2-propanol extract colorimetrically by Karl Fischer titra-
tion. CO was determined by non-dispersive infrared photometry
(calibration with certiﬁed reference gases). Tar yield was calcu-
lated as the TPM yield minus the nicotine and water yields.
Aldehydes (formaldehyde, acetaldehyde, acrolein, crotonalde-
hyde, and propionaldehyde), trapped and derivatized with acidi-
ﬁed 2,4-dinitrophenylhydrazine solution in acetonitrile in two
serially connected impingers, were determined by high-perfor-
mance liquid chromatography with ultraviolet detection.
1,3-Butadiene, isoprene, benzene, toluene, vinylchloride, acry-
lonitrile, and styrene in the gas/vapor phase (TPM removed by
Cambridge ﬁlter ﬁltration) were trapped in cold traps (dry ice/iso-
propyl alcohol bath) containing methanol and analyzed by GC cou-
pled to mass spectrometry (GC/MS) in selected ion monitoring
mode. Deuterated target compounds were used as internal
standards.
Styrene and acetamide in the TPM were extracted from a
Cambridge ﬁlter using acetone and analyzed by GC/MS as
described for, e.g., 1,3-butadiene.
Acrylamide analysis by GC/MS after extraction from a
Cambridge ﬁlter and on-column injection has been described in
detail (Diekmann et al., 2008).
2-Nitropropane was extracted from MS trapped on a silica car-
tridge and analyzed by GC with triple quadrupole mass spectrom-
eter detection (GC/MS/MS) in the chemical ionization mode.
Aromatic amines (o-toluidine, 2-naphthylamine, 4-aminobi-
phenyl, and o-anisidine) were determined by extracting TPM, col-
lected on a Cambridge ﬁlter, with dilute hydrochloric acid,
followed by back extraction with n-hexane after alkalinization,
derivatization with perﬂuoropropionic anhydride (PFPA), clean-
up by solid phase extraction (SFE), and analysis by GC/MS/MS with
triple quadrupole mass spectrometer in the multiple reaction
mode (MRM) via loss of hydrogen ﬂuoride from their PFPA deriva-
tives (Stabbert et al., 2003). Deuterated target compounds were
used as internal standards.
Nitrogen oxides were determined by chemiluminescence after
reduction to nitrogen oxide and reaction with ozone (calibration
with certiﬁed reference gases).
Hydrogen cyanide was trapped in two wash bottles with
sodium hydroxide solution and analyzed by headspace GC with
nitrogen sensitive detection after acidiﬁcation of the samples. For
the evaluation, the external standard method was used.
Volatile N-nitrosamines (N-nitrosodiethylamine (NDEA),
N-nitrosodimethylamine (NDMA), N-nitrosodi-n-butylamine (NBUA),
N-nitrosodi-n-propylamine (NPRA), N-nitrosomethylethylamine
(NMEA), N-nitrosopiperidine (NPI), and N-nitrosopyrrolidine
(NPY)), were collected on a Cambridge ﬁlter and in traps contain-
ing a citrate/phosphate buffer solution. The buffer solution and
the Cambridge ﬁlter extract were combined, extracted with dichlo-
romethane, puriﬁed in sodium hydroxide, concentrated, cleaned
on an alumina column, and analyzed by GC with a thermal energy
analyzer (TEA).
Tobacco-speciﬁc N-nitrosamines (TSNAs: N0-nitrosonornicotine
(NNN), and 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone
(NNK)) were analyzed according a published method (Wagner
et al., 2005). TSNAs were extracted with ammonium acetate solu-
tion from TPM trapped on a Cambridge ﬁlter pad, and analyzed by
HPLC/MS/MS.
Phenols (phenol, catechol, and hydroquinone) were extracted
from a Cambridge ﬁlter with trichloromethane/acetone (1:1). Analiquot of the extract was derivatized with N,O-bis(trimethyl-
silyl)triﬂuoroacetamide and the trimethylsilyl ethers of the phe-
nols were analyzed by GC/MS. Deuterated target compounds
were used as internal standards. Eugenol was measured in a sepa-
rate GC/MS run with different chromatographic conditions after
addition of carvacrol as internal standard.
Polycyclic aromatic hydrocarbons (PAHs) (benz[a]anthracene,
benzo[a]pyrene, benzo[b]ﬂuoranthene, benzo[j]ﬂuoranthene,
benzo[k]ﬂuoranthene, dibenz[a,h]anthracene, dibenzo[a,e]pyrene,
dibenzo[a,h]pyrene, dibenzo[a,i]pyrene, dibenzo[a,l]pyrene,
indeno[1,2,3-cd]pyrene, and 5-methylchrysene) were extracted
from TPM-ﬁlters with pentane/isooctane/undecane, cleaned-up
by SFE, and determined by GC/MS. Deuterated target compounds
were used as internal standards.
Arsenic, cadmium, chromium, nickel, and lead were determined
in the particle phase trapped in quartz glass tubes using electro-
static precipitation. The condensate was dissolved with a dichloro-
methane/methanol mixture, and after addition of nitric acid,
hydrogen peroxide, and water, the samples were subjected to
microwave digestion and analyzed with atomic absorption
spectroscopy.5.4. Basis for normalization
The cigarettes compared in these studies are designed so differ-
ently (TPM ranging from 9 to 46 mg/cigarette, puff count from 8 to
17) that it would be of little use to merely compare smoke compo-
nents yields or assay results on a per cigarette basis. This would not
provide much insight into the mechanistic aspects of smoke gener-
ation and delivery in each of the cigarettes, nor on the possible
impact of differences in their designs on smoke toxicity. By analyz-
ing the data after normalization, the data interpretation shifts
away from the observation of the total smoke quantity, to the dis-
cussion of smoke composition, i.e., smoke quality (Ashley et al.,
2008).
Normalization on a per mg TPM basis is most usually applied in
toxicological evaluations of smoke particulate phase compounds,
as the added TPM often deﬁnes the exposure dose of an assay.
For consistency, the same normalization is also applied to the cor-
responding GVP analyses. This means relating the effects observed
from the GVP compounds with the amount of TPM that accompany
those compounds, and reporting the effects per mass of TPM. The
atmospheric TPM concentration is also the usual reference for
measurement of the inhalation exposure studies. To compare kre-
tek cigarettes, where the range of ﬁller weight is very wide, to
more conventional ‘‘white’’ cigarettes, this approach would appear
to be an adequate basis.
Nicotine normalization has been recommended, however, in the
assessment of tobacco products (Rickert et al., 2007, 2011; Ashley
et al., 2008). This recommendation was founded on the premise
that smokers tend to adjust the amount of smoke they inhale per
day as a function of their nicotine intake. However, little reliable
information can be found regarding kretek cigarette smokers. In
kretek cigarettes, the replacement of part of the tobacco ﬁller by
clove buds (which do not contain nicotine) results in substantially
lower nicotine-to-tar MS ratios than in ‘‘white’’ cigarettes. These
ratios range from about 8.4% for the American-blended reference
cigarette 2R4F to 4.5% and 5.1% for the tested commercial kretek
cigarette brands, and 5.9% for Kretek-R. In so far as a mechanistic
understanding is sought, observations based on nicotine normali-
zation might, therefore, be misleading when comparing kretek
and ‘‘white’’ cigarettes. Because of the essentially descriptive and
mechanistic nature of the studies presented, all data are thus com-
pared and discussed primarily on the basis of their normalization
to TPM.
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5.5.1. General
In vitro cytotoxicity of TPM and the water soluble constituents
of the gas/vapor phase (GVP) of MS was assessed with the Neutral
Red Uptake (NRU) assay (Borenfreund and Puerner, 1985, 1987)
with mouse embryo BALB/c 3T3 cells as previously described
(Roemer et al., 2009).
5.5.2. Test substance
TPM was collected using a Cambridge ﬁlter. GVP was collected
by bubbling the MS fraction that had passed the ﬁlter through a
glass bottle containing ice-cold phosphate-buffered saline (PBS).
The ﬁlters were extracted with dimethyl sulfoxide (DMSO). The
GVP preparation was taken as is. For further details on smoke gen-
eration see Section 5.2. Both smoke fractions were added to the cell
cultures within 50 min (TPM fraction) or 20 min (GVP fraction)
after their collection.
5.5.3. Cells and exposure
Cell cultures were obtained by seeding 1.6  104 cells in culture
medium containing 10% fetal bovine serum (FBS; 100 ll per well).
Approximately 24 h after seeding, the cells were exposed for 24 h
to the smoke fractions, suspended or dissolved in culture medium
containing 5% FBS (100 ll per well) resulting in a ﬁnal concentra-
tion of 1.6% DMSO and 8.4% PBS, or to solvent control (100 ll per
well; culture medium containing 5% FBS, 1.6% DMSO, and 8.4%
PBS). Following exposure, cells were incubated for 3 h in culture
medium containing 5% FBS and neutral red dye (100 ll per well).
Cells were then washed with PBS, the neutral red dye taken up
by viable cells was extracted (ethanol/acetic acid; 100 ll per well),
and the optical density of the neutral red was determined photo-
metrically at 540 nm as a measure for the number of viable cells.
Cytotoxicity assessments were performed in triplicate for each
cigarette and smoke fraction using 8 equidistant smoke fraction
concentrations.
5.5.4. Evaluation
The cytotoxic response was characterized as the EC50 value, i.e.,
the effective concentration that decreased the number of cells by
50% relative to the solvent control. The EC50 values were calculated
from the least square ﬁt of the data to the logistic function
y = a/(1+(x/b)c) with y = photometric absorbance relative to the
solvent control, a = maximum absorbance, x = TPM concentration,
b = EC50, and c = slope at inﬂection point (Putnam et al., 1999).
For each of the three samples, one EC50 value was calculated. The
reciprocal EC50 was chosen to present the cytotoxic effects as a
parameter that numerically increases with increasing toxicity.
5.6. Bacterial mutagenicity
5.6.1. General
Mutagenicity of TPM was assessed in the Salmonella Reverse
Mutation Assay (Maron and Ames, 1983) according to the respec-
tive OECD guideline 471 (OECD, 1997a) as previously described
(Roemer et al., 2012). Determinations were performed in the plate
incorporation assay version with the tester strains TA98, TA100,
TA102, TA1535, and TA1537 in the presence and in the absence
of a metabolic activation system consisting of the post mitochon-
drial fraction (S9) of liver cells from rats treated with Aroclor
1254 (Cytotest Cell Research, Rossdorf, Germany).
5.6.2. Test substance
TPM was collected using Cambridge ﬁlters. The TPM from the
ﬁlters were extracted with DMSO and the extracted TPM
separated from the glass ﬁbers by centrifugation. The TPM-DMSOsuspensions were stored immediately after preparation at
75 ± 1.5 C until use. For further details on smoke generation
see Section 5.2.
5.6.3. Cells and exposure
The bacteria were derived from stock cultures maintained at
196 C with 0.09 ml DMSO/ml cell suspension. They were pre-
pared from overnight cultures inoculated with the ﬁrst cultivation
of the master copies originally received (Bruce N. Ames, Berkeley,
CA). An aliquot (10 ll) of the thawed stock culture was used as
inoculum cultivated in 30 ml of nutrient broth at 36 ± 1 C in a
shaking incubator for approximately 11 h before harvest. The bac-
teria were then in a late logarithmic/early stationary growth phase.
Mutagenicity assessments were performed in duplicate for each
cigarette type. Three doses covering the linear part of the dose/
response curve were prepared and assayed. Each dose was plated
in triplicate.
For plating, bacteria suspended in culture medium, TPM dis-
solved in DMSO or DMSO alone, S9 mix (supernatant after centri-
fugation of liver homogenate from Aroclor 1254-induced rats)
0.1 mol/l phosphate buffer, pH 7.4, were added to the top agar sup-
plemented with histidine (His) and biotin (0.05 nmol each). The
components were mixed and spread evenly on minimal glucose
agar plates. After the top agar hardened, the plates were incubated
in the dark at 36 ± 1 C for 44–48 h. The number of His+ revertant
colonies was determined with an automatic colony counter. In all
experiments several negative and positive strain-speciﬁc and S9-
speciﬁc control substances were concurrently assayed.
5.6.4. Evaluation
The normal mutagenic response for TPM is characterized by a
linear increase in the number of revertants as the amount of TPM
is increased. At higher doses the linearity vanishes (Bernstein
et al., 1982). The mutagenic response reported here was calculated
as the slope (revertants/mg TPM) of the linear portion (excluding
the 0-dose) of the dose–response curve ﬁtted with Poisson-weights
to the data. A single slope was calculated for each of the two
samples.
5.7. Mammalian cell genotoxicity
5.7.1. General
Genotoxicity of eugenol and TPM was assessed in the Mouse
Lymphoma Assay developed byClive et al. (1972), and was per-
formed according to OECD guideline 476 (OECD, 1997b) in the
microtiter plate version (Cole et al., 1986) as described in detail
by Schramke et al. (2006).
5.7.2. Test substance
Eugenol was obtained from Sigma–Aldrich Co. (Cat. E5, 179-1)
purity 99%, lot number 95297LJ-498. For details on smoke genera-
tion see Section 5.2 and TPM collection see Section 5.5.
5.7.3. Cells and exposure
L5178Y/tk+/-3.7.2C mouse lymphoma cells (obtained from E.
Wollny, Cytotest Cell Research, Rossdorf, Germany) growing in sus-
pension culture were cleansed of spontaneously arising tk/
mutants by incubation for 24 h in RM10 medium (RPMI 1640 med-
ium, supplemented with 10% heat-inactivated horse serum,
1 mmol/l sodium pyruvate, 1  105 U/l penicillin G, and 100 mg/l
streptomycin sulfate) containing thymidine, hypoxanthine, metho-
trexate, and glycine.
Each test substance was assessed in two independent assays
with 3–5 concentrations ranging from non-toxic to clear toxicity.
In each study, 1  107 cleansed cells (5  105 cells/ml) were
exposed to neat eugenol or TPM in the absence and presence of a
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fraction of liver cells from rats treated with Aroclor 1254 (S9, Cyto-
test Cell Research, Rossdorf, Germany). Exposure took place in
roller cultures for 4 h at 37 C. For each sample, 3–5 concentrations
were evaluated with one single cell culture per concentration. After
removal of the test substance the cultures were maintained in
RM10 for 3 days (subcultured each day) to allow for phenotypic
expression of induced mutations. Thereafter, 2000 cells per well
were seeded in selective culture medium, RM10 containing
4 lg/ml triﬂuorothymidine, on ﬁve microtiter plates per culture
to select the mutants. In addition, cells were seeded on ﬁve micro-
titer plates at 1 cell/well in non-selective culture medium RM10 to
allow assessment of cloning efﬁciency for the calculation of the
mutant frequency. After an incubation time of 12–13 days, colonies
were detected by the addition of the ﬂuorescence viability indica-
tor resazurin (140 lg/ml, Serotec Düsseldorf, Germany). Fluores-
cence was determined using a microtiter plate reader (excitation:
530 nm; emission: 590 nm) without consideration of marginal
wells. Colony size distribution was determined by calculation of
the cumulative frequency of ﬂuorescence intensity (data not pre-
sented). Negative and positive control substances were assayed
to ensure sensitivity and reproducibility.
5.7.4. Evaluation
The mutagenic response was characterized as mutant frequency
per 105 survivors. Nonlinear curve ﬁts were performed to obtain a
C3B value, i.e., the test substance concentration needed to obtain a
mutant frequency three times the background level (Schramke
et al., 2006).
5.8. Inhalation toxicity
5.8.1. General
The inhalation studies were conducted in an AAALAC-accred-
ited facility (Association for Assessment and Accreditation of
Laboratory Animal Care International, 2006) in Leuven, Belgium
(Philip Morris Research Laboratories) where the care and use of
rats was conformed to the American Association for Laboratory
Animal Science Policy (http://www.aalas.org). The studies were
approved by the local Institutional Animal Care and Use Commit-
tee according to Belgian legislation. They were conducted in com-
pliance with GLP (as revised in 1997) according to OECD 413
guideline (OECD, 1981). Details on the methodology have also been
described elsewhere (Vanscheeuwijck et al., 2002).
5.8.2. Test substance
MS was generated according to ISO standard 3308 and 4387
(ISO, 1991b,a) on a 30-port rotary smoking machine. MS was
diluted with ﬁltered conditioned air immediately downstream
from the pump. Sham-exposed animals were exposed to ﬁltered,
conditioned air only. Analysis of the test atmosphere was regularly
performed to ensure consistent and reproducible delivery of MS.
Smoke samples were collected from within the exposure chambers
at the breathing zone of the rats. In addition to humidity and tem-
perature, the concentrations of TPM and CO were determined at
least once per day or continuously over the exposure period,
respectively, and the particle size distribution was determined
one or two times during the 90-day inhalation period. Nicotine,
eugenol, formaldehyde, acetaldehyde, and acrolein were deter-
mined regularly throughout the exposure period in the test atmo-
sphere (in general > 10 times).
5.8.3. Animals and exposure
Outbred male and female Sprague–Dawley rats (Crl: CDBR)
were obtained from Charles River Laboratories (Raleigh, NC, USA
and L’Arbresle, Cedex, France) and were housed pairwise (samesex) in polycarbonate cages in a room maintained at 22 ± 1 C
and with a relative humidity of 60 ± 1%. The light/dark cycle was
12/12 h. Food and water was available ad libitum with the excep-
tion of during exposure. The age of the rats at the ﬁrst day of expo-
sure was 6–7 weeks and the average weight was approximately
225 g for male and 175 g for female rats. The animals were ran-
domized to the various treatment groups. Each group contained
10 or 20 male and 10 or 20 female rats. The rats were individually
identiﬁed by means of a subcutaneous transponder. They were
exposed nose-only in restrainer tubes for 6 h/day, 7 days/week,
for 90 consecutive days, to target TPM concentrations of 100 lg/l,
150 lg/l, or 200 lg/l. To adapt the rats to the exposure, during
the ﬁrst 4 days the smoke concentration or exposure duration
was gradually increased to the ﬁnal conditions (25%, 50% and
75% of the ﬁnal daily dose on days 1–3). A post-inhalation period
of 42 days was included for a satellite group of animals to investi-
gate reversibility, persistence, and delayed occurrence of smoke-
related effects.
5.8.4. Evaluation
As biomarker of exposure, blood carboxyhemoglobin was deter-
mined in 6 male and 6 female rats/group by GC after reduction to
methane of the CO released from hemoglobin once during the
inhalation period. Nicotine metabolites, including nicotine-N0-
oxide, nornicotine, cotinine, 30-hydroxycotinine, 50-hydroxycoti-
nine, norcotinine, 4-(3-pyridyl)-4-oxobutyric acid, 4-(3-pyridyl)-
4-hydroxybutyric acid, and 3-pyridylacetic acid (usually 8 male
and 8 female rats/group) were determined once by HPLC after
derivatization with 1,3-diethyl-2-thiobarbituric acid in urine
collected over 24 h during and following smoke exposure once
during the inhalation period (Rustemeier et al., 1993). Other
biomarkers of exposure included metabolites of 1,3-butadiene
(3-monohydroxybutylmercapturic acid (MHBMA)) and acrolein
(3-hydroxypropylmercapturic acid (HPMA)). Whole body
plethysmography (10 male and 10 female rats/group) was
performed once during the inhalation period to determine
respiratory frequency, tidal volume, and peak inspiratory ﬂow.
The general condition and health of the rats were assessed by
measuring body weight and food consumption (weekly), and by
performing in-life observations (daily) and ophthalmological
examinations (before and after 90-day exposure).
Lung inﬂammation was investigated by collection of BALF and
determination of total cell population and differential cell count
(neutrophils, alveolar macrophages, lymphocytes). The various cell
populations were determined by ﬂow cytometric analysis after
staining with cell type-speciﬁc antibodies conjugated ﬂuoro-
chromes and counterstaining with propidium iodide (Friedrichs
et al., 2006). In addition a chemokine/cytokine proﬁle of BALF
was determined (Perbio Science, Erembodegem, Belgium). The fol-
lowing chemokines/cytokines were analyzed: Fractalkine, GRO,
MCP1, MIPa, MIP2, MIP3a, RANTES, IL1a, IL1b, IL2, IL4, IL6, IL10,
TNFa, IFNc, and GM-CSF.
Hematology, ophthalmology, and clinical chemistry analyses
were performed according to standard analytical techniques. The
endpoints analyzed conformed to the requirements of OECD 413
guideline (OECD, 1981).
During the scheduled necropsies at the end of the inhalation
and post-inhalation period, gross pathological ﬁndings were
recorded and organ weights determined for major organs. Histopa-
thological evaluation followed OECD guideline 413 with the excep-
tion of the respiratory tract that was examined more in detail:
After decalciﬁcation, the nose was trimmed and four transverse
sections were prepared at deﬁned locations (Young, 1981), i.e.,
level 1 immediately posterior to the upper incisor teeth, level 2
posterior to the incisive papilla, level 3 at the second palatal ridge,
and level 4 between the ﬁrst and second molar teeth. For the
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Sagartz et al., 1992), i.e., level 1 at the arytenoid projections, level
2 at the base of the epiglottis, and level 3 at the vocal folds. The tra-
chea was assessed on a single longitudinal section that included
the bifurcation and carina. At least one section was taken from
the lung, i.e., right lung with cranial, middle, caudal, and accessory
lobes bronchus (Lamb and Reid, 1969), left lung with main bron-
chus (Dungworth et al., 1976). Histopathological endpoints were
reported either as incidence or according to a scoring system with
scores of 1–5 with 1 = mild, 3 = moderate, 5 = severe. Scores of 2
and 4 represent ﬁndings in between.
5.9. In vivo micronucleus assay
5.9.1. General
The potential clastogenicity/aneugenicity of cigarette smoke
was investigated in peripheral blood reticulocytes and bone mar-
row polychromatic erythrocytes of rats in accordance with OECD
guideline 474 (OECD, 1997b) and as described by Van Miert et al.
in more detail (Van Miert et al., 2008).
5.9.2. Test substance
MS was generated and characterized as described under Section
5.7.
5.9.3. Animals and exposure
Outbred male Sprague–Dawley rats (Crl: CDBR) were obtained
from Charles River Laboratories (L’Arbresle Cedex, France). Eight
rats per group were exposed nose-only to a target TPM concentra-
tion of 720 lg/l or to ﬁltered, conditioned air (sham exposure
group) on 4 consecutive days. On the ﬁrst day, the exposure dura-
tion time was 2 times 30 min (with a 30-min interval), on the fol-
lowing days it was 2 times 60 min with a 30-min interval after the
ﬁrst 60 min. Cyclophosphamide (CPA), used as a positive control,
was administered (15 mg/kg, i.p.) in PBS 45–49 h before sacriﬁce
of the animals.
5.9.4. Evaluation
Body weight determinations were performed on day 1 of the
study. Peripheral blood was collected from the retro-orbital plexus
21–26 h after the last exposure to fresh air or MS or 45–49 h after
CPA injection following the MicroFlow protocol M46.01 (Litron
Laboratories, Rochester, NY, USA). Immediately after the peripheral
blood sample collection, the rats were euthanized and bone mar-
row smears prepared as described in detail (Romagna and
Staniforth, 1989; Van Miert et al., 2008).
In the peripheral blood, micronucleus analysis was performed
by ﬂow cytometry of the reticulocyte population, i.e., immature
erythrocytes expressing high levels of the transferrin receptor
CD71 detected by ﬂuorescent antibody reaction. Approximately
20,000 reticulocytes per rat were analyzed for micronuclei. As a
measure of cytotoxicity, the frequency of reticulocytes among a
total of approximately 106 red blood cells was determined.
In the bone marrow, micronucleated polychromatic erythro-
cytes were enumerated by light microscopy on cytocentrifuge
slides stained with Giemsa-May-Grünwald. A total of 2000 poly-
chromatic erythrocytes per rat were analyzed for micronuclei. As
a measure of cytotoxicity, the frequency of polychromatic erythro-
cytes among total red blood cells in the bone marrow was calcu-
lated. A total of 400 red blood cells were counted.
5.10. Statistical analyses
Smoke chemistry data were analyzed using one-way analysis of
variance (ANOVA) for overall comparison (Zar, 1999) followed, in
case of a signiﬁcant result, by a pairwise comparison betweenthe particular experimental cigarette and its respective control
(Dunnett, 1955).
Cytotoxicity data were evaluated by the pairwise comparisons
of the experimental and control group using the t-test (Zar, 1999).
Bacterial mutagenicity data were compared using analysis of
covariance (ANCOVA) followed by pairwise analysis of control
and experimental group using the Dunnett test in case of statistical
signiﬁcances.
Mammalian cell genotoxicity data were compared, using a non-
overlap of the 95% conﬁdence limits of the curve ﬁts as a criterion
for statistical signiﬁcance. In cases were no C3B value was obtained
experimentally a t-test was applied (no extrapolation of the curve
ﬁt).
Data obtained in inhalation studies, if continuous in nature,
were analyzed by ANOVA (when one value was below the quanti-
ﬁcation limit, the Kruskal–Wallis H-test) followed by the Dunnett
post hoc test. Ordinal data from histopathological scoring were
analyzed by the generalized Cochran–Mantel–Haenszel (CMH) test
(Mantel and Haenszel, 1959), partly after rank transformation, fol-
lowed by the Dunnett test. Incidence data were analyzed pairwise
by v2 statistics (Zar, 1999).
Results of the statistical tests were considered signiﬁcant at
p 6 0.05. No adjustments for multiple testing were performed.
To separate spurious, chance-derived differences between data
sets from those due to real effects, a three-step approach was fol-
lowed (such an approach seems to be especially necessary when
dealing with high numbers of false positive signiﬁcances due to
multiple statistical testing):
– A common statistical test to identify statistically signiﬁcant
differences.
– A check, if the analytical method (in the given laboratory) is
inherently capable to reliably discriminate a difference of such
a size (Roemer et al., 2010; Oldham et al., 2012). This criterion
is commonly referred to as the Minimum Detectable Difference
(MDD).
– A check on consistency, i.e., whether a difference can be con-
ﬁrmed by, e.g., dose dependency, similar effects for related
smoke constituents, similar effects for other tester strains in
bacterial assays, or similar histopathological effects at adjacent
sites.
6. Summary of results
6.1. Characterization (Part 2 (Piadé et al., 2014a) and Part 3 (Piadé
et al., 2014b))
Two commercial kretek cigarette brands typical for the Indone-
sian market and a kretek cigarette representing the average of mar-
keted kretek cigarettes (kretek reference cigarette – Kretek-R)
were compared to each other and to the standard American-
blended reference cigarette 2R4F with regards to smoke chemistry,
in vitro cytotoxicity (NRU Assay), and in vitro bacterial mutagenic-
ity (Salmonella Reverse Mutation Assay).
Despite the widely diverse designs of the two selected kretek
cigarettes and the kretek reference cigarette resulting in TPM
yields from 16 to 46 mg/cigarette, their smoke composition and
in vitro toxicity did not show any distinct differences when data
were normalized to equal TPM deliveries. This supports the appli-
cability of the conclusions drawn from our results to a wide range
of kretek cigarette products.
On a per mg TPM basis, the kretek cigarettes appeared to be
similar to American-blended cigarettes in smoke chemistry,
although the yields of nitrogenous compounds were much lower
than would be expected from the mere substitution of one third
of the tobacco ﬁller by clove material. The yields of low molecular
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ﬁller, notably hydrocarbons and aldehydes, were also reduced,
but phenol was increased.
On a per mg TPM basis, the in vitro cytotoxicity of the TPM of
the kretek cigarettes was similar to American-blended cigarettes,
however the cytotoxicity of the GVP of kretek cigarettes was gen-
erally much lower (differences were about 50%). The bacterial
mutagenicity of the kretek cigarettes TPM was generally about
50% lower in all responsive tester strains.
The toxicity of the commercial kretek Gudang Garam and the
Kretek-R was assessed against that of the American-blended refer-
ence cigarette 2R4F in two independent 90-day inhalation studies
in male and female rats. Biological endpoints analyzed were those
listed in OECD guideline 413 but with special emphasis on histopa-
thology of the respiratory tract and lung inﬂammation as measured
by free lung cells counts and differentiation in BALF.
In both studies, the rats (kretek and American-blended 2R4F
groups) responded to the exposure to cigarette smoke with irrita-
tive histological changes in the respiratory tract commonly seen in
cigarette smoke inhalation studies, i.e., hyperplasia, metaplasia,
and atrophy depending on the type and location of epithelium.
As an inﬂammatory response, the number of neutrophils and lym-
phocytes was signiﬁcantly increased in BALF compared to sham-
exposed rats. The response to the smoke was similar for both types
of kretek cigarettes, but distinctly lower compared to the 2R4F.
Respiratory parameters, blood carboxyhemoglobin, and excre-
tion of nicotine metabolites in urine indicated a similar uptake of
MS among all groups exposed to mainstream smoke (American
blended and kreteks). Thus, an anesthetic effect of eugenol in the
respiratory tract, masking the irritancy of smoke, and leading to
an increased inhalation, can be ruled out. Despite the equivalent
uptake of smoke, compared to the rats exposed to 2R4F MS, the
response in the kretek cigarette groups was consistently lower.
As an overall mean, the kretek cigarettes scored about 20% lower
in the most responsive histopathological endpoints (those showing
a mean score of 1.5 and above in any of the smoke-exposed
groups). Noteworthy, the olfactory epithelium at the different loca-
tions in the nose was far less affected in the kretek cigarette
groups. Whereas most rats of the 2R4F groups generally showed
alterations as atrophy, squamous metaplasia or loss of nerve bun-
dles, nearly none of the rats of the kretek cigarette groups showed
such ﬁndings. The lower response in the kretek groups was most
pronounced in the number of inﬂammatory cells in BALF; the num-
ber of neutrophils was more than 80% lower than in the compara-
ble 2R4F groups.
6.2. Mechanisms (Part 4 (Roemer et al., 2014b) and Part 5 (Roemer
et al., 2014c))
The smoke chemistry, in vitro cytotoxicity (Neutral Red Uptake
Assay) and bacterial mutagenicity (Salmonella Reverse Mutation
Assay) of MS from American-blended cigarettes with or without
the addition of 2.5%, 5% or 10% eugenol to the tobacco ﬁller, and
in Indonesian-blended cigarettes without and with the addition
of cloves, cloves extracted with hot ethanol (spent cloves, SC),
and SC replenished with eugenol or clove oil (oleoresins) were
determined. In addition, the genotoxic activity in mammalian cells
(Mouse Lymphoma Assay) was measured for eugenol as a single
substance.
The addition of eugenol to the tobacco reduced the concentra-
tion (per mg TPM) of nearly all smoke constituents measured in
MS when compared to the control cigarette without eugenol. At
the high addition level of 10%, the reductions for most of the smoke
constituents were approximately 35%. Addition of eugenol had no
distinct effect on the in vitro cytotoxicity of TPM while the
cytotoxicity (per mg TPM) of the GVP was decreased up to 40%in a dose-dependent manner. The mutagenicity of the TPM in the
most responsive bacteria strains (TA98, TA100, TA1537; all with
metabolic activation) was about 50% lower at the high eugenol
addition level. These reductions were also dose-dependent.
Eugenol tested as a single substance was found to be active
(increase in mutant frequency by a factor of 2 above control) in
the Mouse Lymphoma Assay with metabolic activation at a con-
centration of 20 lg/ml. However, this concentration proved to be
highly cytotoxic (relative total growth 20% of control). Mutagenic-
ity data at this cytotoxicity level are generally considered not
relevant for the toxicological assessment of a substance (OECD,
1997b).
The addition of SC to Indonesian-blended cigarettes led to
increases, e.g., in 1,3-butadiene, benzene, catechol, pyrene, and
PAHs when expressed on a per mg TPM basis. Decreases were seen
for, e.g., nicotine, water, formaldehyde, acetamide, acrylamide, and
TSNAs. When the SC were replenished with eugenol or oleoresin,
or when untreated cut cloves were added to the tobacco, the yield
of nearly all measured smoke constituents decreased substantially
below the levels found for the tobacco-only cigarette, e.g.,
decreases up to approximately 40% for carbonyls, 2-nitropropane,
and TSNAs. The addition of SC with and without eugenol or oleor-
esins to the tobacco had no distinct effect on the in vitro cytotoxic-
ity of the TPM. The cytotoxicity of the GVP was slightly decreased
by the addition of SC and up to 40% if the SC were replenished
with the oleoresins or full cloves were added. Likewise, the bacte-
rial mutagenicity of the TPM was decreased. In the most sensitive
tester strain TA98 with metabolic activation the reduction
amounted to 30% and 40% for SC with oleoresins or full cloves,
respectively.
The same cigarettes with eugenol and clove and its components
assessed for smoke composition and in vitro toxicity were also
evaluated for inhalation toxicity. The cigarettes with and without
the addition of eugenol were evaluated in a 35-day and the clove
cigarettes in a 90-day rat inhalation study.
The addition of various amounts of eugenol to the tobacco ﬁller
resulted in distinct, concentration-dependent reductions of the
irritative changes in the respiratory tract. Most of the reductions
were up to 80% to 90%, compared to control. At the high euge-
nol addition level, several smoke-induced effects, e.g., the squa-
mous metaplasia of respiratory epithelium and ulceration of the
olfactory epithelium at nose level 2 were absent. A distinct
decrease in the number of cells in BALF, indicative of a lung inﬂam-
matory response, was also absent. Most pronounced was a reduc-
tion in neutrophils up to 70%.
The addition of SC to the tobacco led to increases in irritative
changes in the upper respiratory tract at nose levels 2–4 which
were scored approximately 30% higher than for cigarettes without
the addition of cloves. This was in contrast to the larynx and lung
where the effects of cigarettes with spent cloves were approxi-
mately 30% lower. Replenishment of the SC with eugenol or ole-
oresins negated the changes in the upper respiratory tract which
reverted to the levels found for Indonesian-blended cigarettes
without the addition of any clove components. The addition of full
cloves to the tobacco tended to result in irritative changes approx-
imately 30% lower compared to clove-free cigarettes. The results
for larynx and lung were inconsistent; but addition of full cloves to
the tobacco, on average, resulted in lower responses than in clove-
free cigarettes at all. Neutrophil numbers in BALF were lowest in
rats exposed to MS from cigarettes with SC and the addition of ole-
oresins, i.e., a reduction higher than 95%, compared to clove-free
cigarettes. However, cigarettes with the addition of full cloves
showed also a distinct reduction in the number of neutrophils of
approximately 60%.
In summary, these data suggest that eugenol delivery in
MS may account for about 50% of the observed attenuation in
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added another 50%, probably due to a different spectrum of
combustion products for cloves (compared to tobacco) and possi-
bly due to changes in combustion processes, when compared
to American-blended cigarettes. It can be speculated, that the
oleoresins in the cloves support a more complete combustion,
leading to a lower delivery of cytotoxic/irritating substances.6.3. Ingredients (Part 6 (Roemer et al., 2014a) and Part 7 (Schramke
et al., 2014))
The smoke chemistry, in vitro cytotoxicity (Neutral Red Uptake
Assay) and bacterial and mammalian cell mutagenicity/genotoxi-
city (Salmonella Reverse Mutation Assay, Mouse Lymphoma Assay)
of MS from experimental kretek cigarettes with and without three
ingredient mixes at low (use level) and high (2.5 or 3 times use
level) application rates were investigated. Assessed were a total
of 350 ingredients commonly used in different combinations in
the manufacture of kretek cigarettes.
There were only a few statistically signiﬁcant differences in the
smoke composition between control cigarettes (without added
ingredients) and test cigarettes (with ingredients), but nearly all
of the differences were less than ±20% and there was generally
no evidence of a dose–response relationship to the ingredient level.
The in vitro toxicity, as assessed in the three assays, was virtually
the same for the experimental kretek cigarettes with and without
added ingredient mixes and the respective comparisons did not
show any statistical signiﬁcant differences.
The toxicity of MS from the same cigarettes was assayed in a
90-day inhalation study with a post-inhalation (recovery) period
and a 4-day micronucleus assay in rats.
Respiratory parameters, blood carboxyhemoglobin, and excre-
tion of nicotine metabolites in urine indicated a similar uptake of
MS from the control and the test cigarettes. There were no remark-
able differences in clinical observations, food consumption, body
weight, ophthalmological investigations, clinical chemistry, hema-
tology, organ weights or gross pathology. There were no indica-
tions of ingredient-related histopathological changes in the
respiratory tract, although there were occasional statistically sig-
niﬁcant differences between the control and the test cigarettes
groups at both the end of the 90-day inhalation period and the
post-inhalation time points without consistency (absence of the
same difference at adjacent morphological sites or in the other
gender; absence of an ingredient dose/response relationship). In
the 4-day micronucleus assay the ingredient mixes did not
increase the proportion of micronucleated cells in bone marrow
and peripheral blood relative to that observed in the control group
without ingredient mix. Furthermore, no statistical difference were
seen when the bone marrow cells were stratiﬁed according to
micronucleated polychromatic erythrocytes and reticulocytes.7. Discussion
7.1. Characterization
The in vitro and in vivo studies on Kretek cigarettes, i.e., com-
mercial products and experimental cigarettes, reported here,
revealed consistently the following main results: (i) typical ciga-
rette smoke-related effects, known from studies with American-
blended cigarettes, (ii) no signals of novel toxicity, and (iii) an
unexpected attenuation of pulmonary inﬂammation. It was dem-
onstrated that the yield of smoke toxicants and the in vitro and
in vivo toxicity of kretek cigarette smoke is generally lower on an
equal TPM basis compared to American-blended cigarettes. This
is paralleled by reductions in gas-phase cytotoxic compoundsand particulate-phase mutagenic compounds, as well as dilution
effects (by eugenol) and potentially differences in burning charac-
teristics. When based on an equal nicotine basis, several of the tox-
icity endpoints in kretek cigarettes become equivalent to
American-blended cigarettes. As such, the data do not indicate an
increased hazard potential of kretek cigarette smoke compared to
the smoke of American-blended cigarettes. However, determining
the risk potential associated with kretek cigarette smoking
requires population-based exposure data. As reported previously,
we are only aware of one small clinical study that showed no
change in the uptake of smoke by regular smokers when switching
from their own brands to kretek cigarettes (Malson et al., 2003).
Whether the warning issued by CDC (1985) – and which the
current Fact Sheet still contains (CDC, 2014) – regarding acute lung
injury (i.e., lung damage that can include a range of characteristics
such as decreased oxygen, ﬂuid in the lungs, leakage from capillar-
ies, and inﬂammation), especially among susceptible individuals
with asthma or respiratory infection relates to eugenol effects or
the hazard potential of kretek cigarette smoke remains to be estab-
lished. Although we observed a substantial reduction in the rela-
tive and absolute number of neutrophils in BALF as the main
indicator of lung inﬂammation in rats exposed to the smoke of kre-
tek cigarette vs. that of American-blended cigarettes, highlighting
potential adverse health consequences in susceptible individuals
when smoking kretek cigarettes is still justiﬁed as a public health
objective.
Kretek cigarette smoke contains eugenol due to the addition of
cloves. Eugenol exhibits a mild anesthetic effect. This effect of
eugenol is well known (Sell and Carlini, 1976; Dallmeier and
Carlini, 1981; Brodin, 1985; Lee et al., 2005), in part explainable
(Brodin, 1985; Lee et al., 2005), and used in medicine (Markowitz
et al., 1992; Garibaldi et al., 1995). The fact that eugenol is a com-
ponent of kretek cigarette smoke has raised further concern, as
eugenol on its own has been shown as genotoxic in the forward
mutation assay in mouse lymphoma cells (Tennant et al., 1987;
Myhr and Caspary, 1991). This activity, albeit at a highly cytotoxic
concentration, could be reproduced in one of our reported studies.
Other assays, such as the chromosomal aberration test, appeared to
be equivocal, even when performed in the same laboratory (Stich
et al., 1981; Bean et al., 1992; Bean and Galloway, 1993). There
are more than 20 published studies that show that eugenol has
no mutagenic activity in Salmonella typhimurium (Miller et al.,
1986; Tennant et al., 1987; Azizan and Blevins, 1995) including
one study that shows that eugenol reduces the mutagenicity of
TPM in S. typhimurium (Sukumaran and Kuttan, 1995). Life-time
oral administration studies in rats and mice do not show a carcin-
ogenic effect (Miller et al., 1983; NTP, 1983).
7.2. Mechanisms
The results obtained in the mechanistic studies suggest that the
pyrolysis of the clove matrix (with distinctly reduced eugenol con-
tent) yields a smoke that has a somewhat higher toxicity than the
smoke produced from pyrolysis of tobacco. The oleoresins and
especially the eugenol in the clove matrix, however, show an even
stronger effect of reduced toxicity. There is one limitation to the
current studies, it was not technically feasible to remove the oleor-
esins completely from the clove matrix. Nevertheless, there are
obviously several factors that work together resulting in a
decreased toxicity of smoke from cigarettes with the addition of
full cloves, compared to cigarettes without cloves. In vitro, the ole-
oresins, probably by a change in burning characteristics, lead to
decreased concentrations of toxicants in the gas and particulate
phase of kretek cigarette smoke. Furthermore, as eugenol with its
low in vitro toxicity is found exclusively in the particulate
phase of MS, it dilutes the particulate phase and can exert its
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might play a distinct role in the experimental cigarettes, where
pure eugenol was added in rather high amounts to the cigarettes.
In vivo, the known anti-inﬂammatory activity of eugenol (Sell
and Carlini, 1976; Queiroz et al., 2009; Pramod et al., 2010; Park
et al., 2011) likely adds to the remarkably reduced inﬂammatory
effects in the lung and irritative changes in the epithelia of the
respiratory tract.
7.3. Ingredients
In the studies that assessed the effects of 350 ingredients added
to kretek cigarettes in various combinations in the manufacture of
these cigarettes, the addition of the ingredients did not lead to an
increased yield of toxicants or an increase of the in vitro or in vivo
toxicity of the smoke. Thus, the current results conﬁrm the results
obtained with 260 of these ingredients that had been already
tested in American-blended cigarettes (Carmines, 2002). It further
adds to the validity of the testing paradigm, that the construction
of the cigarette, where the ingredients are tested on, does not play
a role (Dempsey et al., 2011; DIN, 2014).
The testing program for the ingredients, in vitro and in vivo,
included those assays that are generally used for this purpose
(Dempsey et al., 2011). Furthermore, the amount of testing, the
interpretation and ﬁnal assessment of the data followed the recent
recommendations elaborated by a German Working Group on the
‘‘Toxicology of Additives’’ (DIN, 2014) and, thus, can be considered
as state-of-the-art.
8. General conclusion
The toxicity of kretek cigarettes was assessed in a comprehen-
sive chemical-analytical, in vitro and in vivo study program. This
assessment included evaluation of different kretek cigarette prod-
ucts, comparisons to American-blended products, effects of cloves
and their components, and the effects of ingredients added to the
ﬁller of clove cigarettes. None of these investigations revealed
any toxicological concern above those already associated with
combustible cigarette products.
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